Navigation Links
Breast cancer risk not increased by acrylamide

Good news for French fry lovers? Yes! It has been found out that there is no association between acrylamide a compound found in // baked and fried food -- and breast cancer. More than 43,000 women were studied which also included 667 breast cancer patients.

The participants had their average daily intake of acrylamide monitored. No evidence of an increased risk of breast cancer in the women whose intake was higher was documented. Acrylamide was first discovered in 2002 and is formed as a result of a reaction to amino acids and sugars found in foods heated to high temperatures.

However, it is important to examine the risk associated with other cancers as well as neurological conditions. So far, dietary levels of acrylamide do not increase the risk of bladder, large bowel, and kidney cancers.
'"/>




Page: 1

Related medicine news :

1. Consensus on "Combination Therapy" for Breast Cancer
2. Breast cancer treatment to be determined by gene test
3. Breast Feeding prevents obesity later on in life
4. Breast milk is essential
5. Breast Cancer Surgery Causes Psychological problems
6. Breast cancer evidence
7. Letrozole Beats Tamoxifen in Breast Cancer Therapy
8. Breast screening among diabetic women
9. Breast feeding can alter hormones
10. Diet, Sunlight connected to Breast Cancer Risk
11. Additional Radiotheraphy for Breast Cancer
Post Your Comments:
(Date:5/15/2008)...ural organic atoms with metal complexes, scientist...e of enzyme inhibitor capable of blocking a bioche...lopment. , Based on studies in human melanoma c...w ways to treat cancer by dampening the overactive...growth. , Details of the study, to be published ...
(Date:5/15/2008)...audit of community hospitals associated with Fox C... partnership between a major academic cancer cente... and community hospitals, where most care is provi...ffectively disseminating advances in cancer treatm...ive Cancer Center in Philadelphia, first establish...
(Date:5/15/2008)...he anti-inflammatory medication also known by the ...uces a specific proliferation measurement of preca...from The University of Texas M. D. Anderson Cancer...e of COX-2 inhibition toward preventing lung cance...disease. , The study is the first large randomiz...
(Date:5/15/2008)...re/ -- JumpStart Inc., the Northeast Ohio,venture ...th of innovative,early-stage businesses and ideas,...0 in CerviLenz(TM), Inc. The Cleveland-based compa...inistration cleared medical,device that allows obs...egnant women, which has been established by the Na...
Breaking Medicine News(10 mins):Health News:Novel enzyme inhibitor paves way for new cancer drug 2Health News:Novel enzyme inhibitor paves way for new cancer drug 3Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3Health News:CerviLenz Receives JumpStart Investment 2Health News:CerviLenz Receives JumpStart Investment 3
...rom Georgia Institute of Technology, US and the Jo...h the pathogenic bacteria defends itself from the ...ave reported the results of their research in the ... cause food borne illness by producing toxins in t...
...om Asan medical center has reported in the Journal...ffective in treating emotional stress or emotional...earchers conducted their study in 152 patients who...months and the results found that the study patien...
...nts with breast cancer and adversely affects the l...ished in the January 15 issue of the American Jour...om a Chinese study are identical to conclusions th...udies and ponit to the fact that obesity seems to ...
...jected alarming results that the practice of inter... the risk of contracting HIV virus by a margin of ...ased risk if detergents are used for the same acco...esults of this research can be found in Aids journ...
Other Medicine News:Health News:Increased Risk Of HIV Transmission Following Vaginal Washing 2
(Date:5/15/2008)...A Trial data reports in third quarter ...RNewswire-FirstCall/ -- VIA Pharmaceuticals,Inc. ...on the development of,compounds for the treatment ... has completed patient enrollment in its acute cor...f three Phase 2 trials investigating VIA-2291,the...
(Date:5/15/2008)... Meeting of The American Society of Ped...INE, Calif., May 15 /- IDM ...announced the presentation of updated data,from a ...e (L-MTP-PE) in,patients with lung metastases as a... and often fatal bone tumor that typically affects...
(Date:5/14/2008)...swire-FirstCall/ -- Progen,Pharmaceuticals Limited...Company has resumed patient enrolment in the phase...polyamine analogue, PG-11047 (formerly CGC-11047),...mmenced development of PG-11047 - the lead clinica...llowing its acquisition of,Cellgate, Inc earlier t...
(Date:5/14/2008)...PacificGMP, the leader in utilizing,single-use bio...ts client,partners, announced today that it has co...ng practices) standards for a Trius Therapeutics P...orked closely with Trius on this GMP fill,project,...nd complete,within a narrow deadline," said Leigh ...
Breaking Medicine Technology:VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 2IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 3IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 4IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 5IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program 6Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2PacificGMP Completes GMP Product Fill for Trius Therapeutics 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 1VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 1094 3Grid computing offers new hope in race against bird flu 3001 1Grid computing offers new hope in race against bird flu 3001 2Fungus genome yielding answers to protect grains people and animals 699 1Fungus genome yielding answers to protect grains people and animals 699 2Fungus genome yielding answers to protect grains people and animals 699 3The reservoir of Marburg virus identified in a species of fruit bat 697 1The reservoir of Marburg virus identified in a species of fruit bat 697 2The reservoir of Marburg virus identified in a species of fruit bat 697 3
...ed on Glucose Homeostasis Effects in,Normal and Di...-FirstCall/ -- In a 14-day,Phase IIa study of the...tional compound dapagliflozin, a selective inhibit...inistered alone or,concomitantly with metformin in...s due to adverse events and no serious adverse,eve...
.../PRNewswire/ -- Novagali Pharma, an,emerging pharm...sents positive results of its pivotal phase III cl...linical study of Vekacia(R) in,children suffering ...Afro-Asian Congress of ophthalmology (AACO) held f...KC is a severe form of chronic allergic conjunctiv...
Other Medicine Technology:First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 2First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 3First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 4First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 5First Phase II Short-Term Study on Dapagliflozin Shows Results on,Safety, Tolerability and Glycemic Markers in Subjects With Type 2,Diabetes 6Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 2Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 3Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis 4
Transfuse-ID™, a bedside Transfusion Verification System, is used by hospitals to ensure that a patient receives the specific unit(s) of blood that was typed and crossmatched for them. It has th
...stem helps ensure a safe care environment by autom...he unit dose level. The automated process and reli...ion and handling of all items, including vials, am...reparations and more. This saves valuable time for...
...nsfusion Safety Management system ensures your pat...care. , BloodTrack SafeTx uses the AutoPPI™ b...nt from sample collection to transfusion. SafeTx c...uces the need for bedside paperwork and associated...
wBloodCare™ provides functionality at the bedside to ensure that the correct patient receives the correct blood product.
Medicine Products: